Tasquinimod (oral treatment, day 0 or 1 to end of experiment), q-compound targeting TLR4 signaling of S100A9, alone, with SurVaxM peptide and GM-CSF or with tumor-targeted superantigen. Here, CSF2 is linked to neoplasm.